Here are some more links:
An article in the Washington Post from Dr Laura Edwards-Leeper & Erica Anderson
(Note: Dr Anderson is a male transitioner who is also a gender clinician)
“ I think this is a bad idea in 99% of circumstances. Professionals who know what they’re doing should be involved; and by not including parents, it ultimately makes the situation worse for the kid (unless the parent is abusive- that’s the 1%). I’ve actually never seen this go well”
www.washingtonpost.com/outlook/2021/11/24/trans-kids-therapy-psychologist/
mobile.twitter.com/drlaurael/status/1462968319636480004
The Washington Post article points out that many clinicians are not following the WPATH guidelines of comprehensive assessment and rmental health support.
The standards of care recommend mental health support and comprehensive assessment for all dysphoric youth before starting medical interventions. The process, done conscientiously, can take a few months (when a young person’s gender has been persistent and there are no simultaneous mental health issues) or up to several years in complicated cases. But few are trained to do it properly, and some clinicians don’t even believe in it, contending without evidence that treating dysphoria medically will resolve other mental health issues. Providers and their behavior haven’t been closely studied, but we find evidence every single day, from our peers across the country and concerned parents who reach out, that the field has moved from a more nuanced, individualized and developmentally appropriate assessment process to one where every problem looks like a medical one that can be solved quickly with medication or, ultimately, surgery. As a result, we may be harming some of the young people we strive to support — people who may not be prepared for the gender transitions they are being rushed into.
_
Gender-Affirming Treatment of Gender Dysphoria in Youth: A Perfect Storm Environment for the Placebo Effect—The Implications for Research and Clinical Practice
Alison Clayton. 14 November 2022
Introduction
In the last decade, there has been a rapid increase in the numbers of young people with gender dysphoria (GD youth) presenting to health services (Kaltiala et al., 2020). There has also been a marked change in the treatment approach. The previous “common practice” of providing psychosocial care only to those under 18 or 21 years (Smith et al., 2001) has largely been replaced by the gender affirmative treatment approach (GAT), which for adolescents includes hormonal and surgical interventions (Coleman et al., 2022). However, as a recent review concluded, evidence on the appropriate management of youth with gender incongruence and dysphoria is inconclusive and has major knowledge gaps (Cass, 2022). Previous papers have discussed that the weaknesses of the studies investigating the efficacy of GAT for GD youth mean they are at high risk of bias and confounding and, thus, provide very low certainty evidence (Clayton, 2022a, b; Levine et al., 2022). To date, however, there has been little discussion of the inability of these studies to differentiate specific treatment effects from placebo effects. Of note, the term “placebo effect” is no longer used to just simply refer to the clinical response following inert medication; rather, it describes the beneficial effects attributable to the brain-mind responses evoked by the treatment context rather than the specific intervention (Wager & Atlas, 2015). This Letter argues that the current treatment approach for GD youth presents a perfect storm environment for the placebo effect. This raises complex clinical and research issues that require attention and debate.
Sections include:
A Brief Introduction to the Gender-Affirming Treatment Model for Children and Adolescents with Gender Dysphoria
Risks of Gender-Affirming Medical and Surgical Treatments
A Recent Example from Medical History of the Dangers of Medical Advice Based on Weak Evidence: The Iatrogenic Tragedy of Prone Infant Sleep Position and Sudden Infant Death Syndrome
Gender-Affirming Treatment for Youth with Gender Dysphoria: A Perfect Storm for Placebo Effect
Overstatement of the Certainty of Benefits and Under-Acknowledgment of Risks
The Dangers of an Exaggerated Suicide Narrative
An Excessively Negative Portrayal of the Previous Standard and Current Alternative Treatment Options
Clinicians’ Media and Social Media Promotion of Gender Affirmative Treatment
The Exclusive Promotion of Gender-Affirming Treatments within Child and Adolescent Gender Clinics
Conclusion
In conclusion, this Letter has noted that although GAT for GD youth lacks a rigorous evidence base, it is undertaken as routine medical treatment in a strongly placebo effect enhancing environment. It is within this environment that research into its effectiveness is being undertaken. One consideration raised by this relates to clinical practice: When does such a strongly placebo effect enhancing environment meet optimal clinical practice standards? When, if at all, does it veer into the territory of unethical practice that involves deception and undue influence? This Letter has also highlighted that such a placebo effect enhancing environment presents grave problems for research (particularly non-DBRCT research). It seems unlikely that the current research being undertaken in this field will be able to untangle benefits that are due to the placebo effect from those due to the interventions’ specific effectiveness. Thus, especially given the adverse risk profile of the hormonal and surgical interventions, it may be that yet again well-intentioned physicians are engaging in medical practices that cause more harm than benefit (Clayton, 2022b). The research and clinical conundrums presented in this Letter have no easy answers. However, as a first step, there is an urgent need for more awareness of the placebo effect and for rigorous and thoughtful debate over how best to proceed in research and clinical practice in this area of medicine.
link.springer.com/article/10.1007/s10508-022-02472-8
_
Bone density issues caused by GnRH
Bone Health in the Transgender Population
Published online 2019 Jul 2.
Micol S. Rothman and Sean J. Iwamoto
www.ncbi.nlm.nih.gov/pmc/articles/PMC6709704/
This
Also unknown are the long-term effects of puberty blockade, the effect of changes in body composition and the optimal type, timing, dosage, and route of administration of GAHT for bone outcomes.
Conclusion
The results of the studies that reported impact on the critical outcomes of gender dysphoria and mental health (depression, anger and anxiety), and the important outcomes of body image and psychosocial impact (global and psychosocial functioning), in children and adolescents with gender dysphoria are of very low certainty using modified GRADE. They suggest little change with GnRH analogues from baseline to follow-up.
And
GnRH analogues are frequently employed to provide puberty blockade in adolescents with gender incongruence or gender dysphoria. From their use in other medical conditions such as prostate cancer, their deleterious effects on the bone are well known, although these have the potential to be reversible if treatments are stopped or add back therapies can be given
And
However, Z-scores in the trans boys also showed an expected drop during GnRHa treatment. Similarly, they did not fully make up their bone loss as Z-scores at age 22 were still lower than baseline
Meaning, the authors acknowledge little is known about the lasting effects of puberty blockers. In this study, they propose some positive effect from cross sex hormones for females but ths results show that it doesn’t really make up the loss from puberty blockers.
PLUS
Just adding this piece about bone density for young transitioners here:
segm.org/the_effect_of_puberty_blockers_on_the_accrual_of_bone_mass
1st May 2021
Dr Michael Biggs (an advisor to SEGM) has been calling for the release of data from the Tavistock’s experiment since 2019. A subset of the data were finally released following the judicial review into puberty suppression at the Tavistock clinic. Biggs’ reanalysis has just been published in the Journal of Paediatric Endocrinology and Metabolism. It finds that after two years on GnRHa, the Z-scores for a significant minority of the children had declined to a level that should trigger clinical concern.
The discredited study where a Yale researcher tried to convince the world that gender treatments improve mental health of transitioners.
https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2019.19010080
https://www.thepublicdiscourse.com/2020/09/71296/?fbclid=IwAR1qhY36S81bxLIL-Gm04MemcwA8R0OBpG5iCy_CrUM6tGttrO98Un-WLTE
A major correction has been issued by the American Journal of Psychiatry. The authors and editors of an October 2019 study, titled “Reduction in mental health treatment utilization among transgender individuals after gender-affirming surgeries: a total population study,” have retracted its primary conclusion. Letters to the editor by twelve authors, including ourselves, led to a reanalysis of the data and a corrected conclusion stating that in fact the data showed no improvement after surgical treatment. The following is the background to our published letter and a summary of points of the critical analysis of the study.
Two prominent transwomen clinicians, one who could led WPATH next year have stated they are against some of the current practices in trans health. Marcy Bowers and Eric Anderson. Particularly fast tracking to hormonal treatments. Article by Abigail Shrier.
bariweiss.substack.com/p/top-trans-doctors-blow-the-whistle